Indication

Cachexia due to HIV

Cachexia due to human immunodeficiency virus (HIV)—historically categorized as HIV wasting syndrome—is a systemic metabolic and catabolic complication affecting individuals with HIV infection, most frequently observed in advanced disease or uncontrolled viremia. Read more about Cachexia due to HIV

19 drugs 18 manufacturers

Advertisement

Drugs that treat it

Common Cachexia due to HIV therapies.

Showing 10–18 of 19 drugs

Filter & compare in the drug finder →Opens the drug finder with Cachexia due to HIV preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Cachexia due to HIV.

Cachexia due to human immunodeficiency virus (HIV)—historically categorized as HIV wasting syndrome—is a systemic metabolic and catabolic complication affecting individuals with HIV infection, most frequently observed in advanced disease or uncontrolled viremia.

It predominantly impacts the musculoskeletal and metabolic systems, presenting clinically as severe, involuntary weight loss characterized by a disproportionate depletion of lean body mass and skeletal muscle, often accompanied by persistent diarrhea, weakness, or fever lasting at least 30 days.

Pathophysiologically, the condition is driven by sustained immune dysregulation and elevated proinflammatory cytokines—such as tumor necrosis factor-alpha and interleukin-6—which induce hypermetabolism, altered protein synthesis, and anorexia, frequently exacerbated by enteropathy and nutrient malabsorption.

Personalize your experience

Follow Cachexia due to HIV and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it